Empowering scientists to their next breakthrough

Our purpose – to serve life scientists to help them achieve their mission, faster – drives everything we do.

By providing life scientists with critical biological tools and reagents needed for research, drug discovery and diagnostics, we are helping advance scientific discovery, resulting in better health outcomes and improving lives.

We recognise that we succeed only because we help our customers achieve their goals, faster. We are committed to increasing and improving the ways in which we are able to support life scientists and achieving this in a way that benefits our shareholders and our other stakeholders.

As we continue to execute our strategy to deliver sustainable performance and growth, our culture will help drive success.

We will – continue to dedicate ourselves to our customers, anticipating and responding to their needs in order to deliver an exceptional experience; be audacious in our approach to innovation and in finding solutions to existing and new biological questions; and earn trust by delivering quality products and services with agility and speed, executing on our plans and, at all times, acting responsibly and with integrity.

Alan Hirzel
Chief Executive Officer

Dedicated to excellence

How Abcam's scientists are helping the research community move closer to a cure for Parkinson's disease.

Today, there are over six million people around the world living with Parkinson's disease.

Through true partnership, Abcam and the Michael J Fox Foundation have shown unwavering commitment and dedication to co-creating innovative tools that are helping to accelerate Parkinson's research across the global community.

To date, the partnership has put over 50 new antibodies into the hands of the global research community, which have been cited in over 150 peer-reviewed research papers.

This research is generating insights that will one day support finding a cure for this condition.

Visit abcam.com/neuroscience/parkinsons-disease to find out more


bollé

Purpose in action



Audacious innovation

How an audacious approach to innovation is helping advance research in rare disease areas with high unmet medical need.

Around the world, researchers and organisations are working hard to better understand the estimated 7,000 rare diseases that impact human health, defined as those that impact fewer than 1 in 2,000 people.

This bold, pioneering work is shedding new light on these disorders, informing and supporting the development of new therapies and treatment – although ready access to effective research tools is often a challenge, holding back faster progress.

One such organisation is the Loulou Foundation, which is focused on finding a cure for CDKL5 Deficiency Disorder (CDD), involving the mutation of a gene essential for normal brain development and function. The lack of quality research reagents for CDKL5 has been a significant hurdle to the understanding of the biology of this devastating disorder, and to the development of effective therapies.

By combining the technical expertise of our teams with the disease-specific expertise of groups, like the Loulou Foundation, we are helping to support effective rare disease research through the innovation of precision research tools.

Visit abcam.com/Loulou to find out more about Abcam's partnership with The Loulou Foundation

Embracing agility

How an agile approach to new product development is helping increase our knowledge of epigenetics.

Epigenetics is defined as the study of heritable changes of DNA, not involving changes in a DNA sequence, that regulate gene expression. Whilst the study of epigenetics has been around for many years, its impact on biology and human disease is still largely unknown. What is known is that epigenetics is disease agnostic, with new and varied biomarkers being identified on a daily basis that are common to diseases as diverse as cancer and neurodegeneration.

Abcam was proud to be one of the first reagent suppliers to bring antibodies to the market to assist the study of epigenetic modifications to RNA. These tools are enabling the global research community to uncover insights and unlock this complex area of biology.

During the year we launched 25 antibodies to modified RNA. These products join over 3,000 others across our various ranges that are helping to support the study of epigentics. Interactive partnerships with leading academic experts have allowed us to respond at pace to meet this expanding demand.

Visit abcam.com/epigenetics to find out more about Abcam's range of antibodies supporting epigenetics research


EMERGENCY